Por: MarketWatch Business July 12, 2023
(VMW) was rising 2.3% in premarket trading after the European Commission approved ‘s (AVGO) $61 billion acquisition of the software company. rose 0.6%. (NVDA) gained 0.5% in premarket trading on a report that said Arm was discussing bringing in while the chip designer moves ahead with plans for an initial public offering later this year. One person familiar with the discussions told the Financial Times that was looking for Arm’s total... + full article
ABC News USA Business July 12, 2023
BRUSSELS -- The European Union on Wednesday slapped a $475 million fine on U.S. biotech giant Illumina for buying out cancer-screening company Grail without the approval of the 27-nation bloc's antitrust watchdog, the latest setback for the deal.Illumina announced an $7.1... + más
Biotech company Illumina pushes back against Carl Icahn’s proxy fight over $7.1 billion Grail deal | CNBC
FTC orders Illumina to unwind $7B deal for cancer test developer Grail | Fox Business
ABC News USA Health July 12, 2023
ABC News USA Tech July 12, 2023
WPLG Local 10 USA Tech July 12, 2023
BRUSSELS – The European Union on Wednesday slapped a $475 million fine on U.S. biotech giant Illumina for buying cancer-screening company Grail without regulators' approval, the latest setback for the deal.Illumina announced an $7.1 billion acquisition of Grail in 2020,... + más
MarketWatch USA Business May 25, 2023
Illumina is holding its annual meeting at 1 p.m. Eastern time, at which the results of the proxy vote will be announced. The meeting will be held virtually, and is only open to shareholders. The stakes are high for Icahn, who needs a win. The Wall Street lion is facing an from a... + más
Illumina ordered by FTC to unwind $7b Grail deal from 2021 | The Boston Globe
The New York Times USA Business April 03, 2023
The Federal Trade Commission on Monday ordered Illumina, the leading maker of gene-sequencing machines, to divest Grail, a cancer-test developer.The move by the F.T.C. is the latest development in a case seen by antitrust experts as a to stop big companies from buying fledgling... + más
CNBC USA Health March 21, 2023
In this articleCarl IcahnAdam Jeffery CNBC Biotech company pushed back Monday against Carl Icahn's proxy fight over the company's acquisition of cancer test developer Grail, saying the activist investor's board nominees do not add value. The San Diego-based DNA... + más
Carl Icahn claims Illumina directors got extra insurance to close 'disastrous' $7.1 billion Grail deal | CNBC
Icahn proposes three candidates for Illumina’s board — Here’s what could be next in the battle | CNBC
About iurex | Privacy Policy | Disclaimer |